Love her or roll your eyes, Cathie Wooden’s bets are nearly inconceivable for traders to overlook.
With clear theses and gutsy bets early on, the ARK Make investments boss is keen to flip the script when the details change.
That playbook proved remarkably efficient this yr, with ARK Innovation ETF (ARKK) fill up 58% yr up to now, blowing previous broader benchmarks whereas drawing recent consideration to “disruptive innovation.”
Currently, she’s been laser-focused on the following leg of the cycle.
To date, it has been biotech shares with actual catalysts on the horizon, together with AI-adjacent platforms the place knowledge, funds, and e-commerce intersect.
Behind the scenes, Wooden is tilting the portfolio to successfully replicate that view. In her newest portfolio reshuffling, we are able to spot outlines in a few locations specifically.
The primary consists of selective provides the place science or software program is nearing an inflection level, together with measured trims the place multiples ran faster than fundamentals.
The strikes suggest a methodical reweighting towards what may doubtlessly matter essentially the most within the again half of this yr.
Cathie Wooden continues to shift her portfolio towards biotech and AI-adjacent platforms, signaling the place she sees the following wave of innovation.
Picture supply: SOPA Photographs/Getty Photographs
Cathie Wooden cuts Shopify stake, piles into Intellia and Block
Cathie Wooden simply despatched a transparent sign together with her strikes, together with her seeking to trim stretched winners whereas doubling down on what comes subsequent.
The ARK Make investments founder simply made arguably her largest biotech bets of 2025, selecting up a outstanding 750,000 shares of Intellia Therapeutics (NTLA) value $19.2 million.
For some coloration, the favored gene-editing participant is concentrated on CRISPR therapies for ATTR amyloidosis (NTLA-2001) and hereditary angioedema (NTLA-2002). These applications are being billed as transformative “one-and-done” remedies for high-value uncommon ailments.
With key knowledge milestones forward, Wooden is positioning for a biotech re-rating that might doubtlessly unfold over the following yr.
Fund supervisor buys and sells:
- Cathie Wooden drops $12 million on resurgent tech large
- Cathie Wooden sells shares in main AI inventory
- Why 2 main asset managers simply suspended investments into silver
Her urge for food for innovation didn’t cease there.
ARK additionally made a sizeable $30.7 million funding in Block, scooping up a wholesome 385,585 shares throughout ARKK, ARKW, and ARKF.
The outsized guess underscores Wooden’s conviction in fintech infrastructure, with AI and funds converging.
On prime of that, smaller and comparatively strategic additions adopted.
ARK added 268,833 DraftKings shares value $8.9 million, 17,579 Amazon shares valued at $3.9 million, and 14,881 Alibaba shares value a hefty $2.6 million. It additionally grew its genomic footprint, including 562,505 Pacific Biosciences inventory and 274,939 10x Genomics shares.
Associated: JPMorgan revamps Google inventory goal on quiet game-changer
On the flip facet, Wooden stunned every body by trimming a couple of longtime favorites. Shopify (SHOP) was ARK’s largest sale, offloading 281,738 shares value $48.7 million.
For perspective, Shopify’s Q2 gross sales jumped 31% to $2.68 billion, whereas GMV hit $87.8 billion, and free-cash-flow margins hovered close to 16%, with rising prices and a cautious revenue outlook prompting trims.
Additionally, ARK bought 139,222 shares of Palantir, 50,832 shares of Roblox, together with smaller cuts to Ionis Prescription drugs and Iridium Communications.
Cathie Wooden’s buys
- Intellia Therapeutics: +750,000 shares, $19.2 million
- Block: +385,585 shares, $30.7 million
- DraftKings: +268,833 shares, $8.9 million
- Amazon: +17,579 shares, $3.9 million
- Alibaba: +14,881 shares, $2.6 million
- Pacific Biosciences: +562,505 shares
- 10x Genomics: +274,939 shares
Wooden’s sells
- Shopify: -281,738 shares, $48.7 million
- Palantir: -139,222 shares, $4.1 million
- Roblox: -50,832 shares
- Ionis Prescription drugs: Diminished place
- Iridium Communications: Diminished place
Cathie Wooden warns of an AI “reality check” as valuations soar
Cathie Wooden isn’t calling out an AI bubble as but, however she’s clearly flashing a warning gentle.
Talking at Saudi Arabia’s Future Funding Initiative in Riyadh, the ARK Make investments CEO mentioned, regardless of being bullish on AI and its long-term influence, AI valuations may doubtlessly face a “reality check.”
Associated: Palantir quietly makes huge AI battle play
Her warning comes at a time when traders proceed to pour billions into tech giants and AI-powered names, together with AMD, Nvidia, Palantir, and others, pushing the red-hot sector to frothy highs.
Wooden feels that traders misunderstand the connection between innovation and rates of interest, noting that they’re “not inversely correlated over history.”
These feedback come as a relative shock, contemplating that ARK’s personal innovation funds in ARKK, ARKW, and ARKF proceed rallying arduous this yr, led by wholesome publicity to AI-linked names.
Nonetheless, Wooden’s message to traders is obvious: The following 12 months may check simply how a lot of the AI growth is priced in at the moment.
Associated: High analyst calls ‘kick within the pants’ for S&P 500
